Core Insights - Wall Street is entering earnings season with reports from major financial institutions such as Wells Fargo, Goldman Sachs, Citigroup, Bank of America, Morgan Stanley, and JPMorgan expected [1] - Despite a significant sell-off on Friday, there is an expectation that the market's multi-year rally is not over [1] Earnings Reports - Earnings season begins on Tuesday with Blackrock, Wells Fargo, and Goldman Sachs reporting; all three have performed well this year and are not heavily impacted by the trade war [3] - Johnson & Johnson and Domino's Pizza will also report on Tuesday, with expectations for Johnson & Johnson to have the best quarter in its sector, while Domino's may miss estimates [4] - On Wednesday, Bank of America, Morgan Stanley, and Abbott Laboratories will report; Morgan Stanley has shown positive results recently, and Abbott is considered reliable [4] - Thursday will see earnings from Taiwan Semiconductor, CSX, and Charles Schwab, with positive figures expected from Taiwan Semiconductor, which supplies chips to Nvidia and AMD [6] - American Express and SLB will report on Friday; American Express shares typically decline post-earnings, while SLB management is known for transparency [7] Market Context - The week is complicated by a sharp decline in Treasury yields, which usually indicates better economic conditions ahead, but current sentiment is negative [2] - Salesforce's annual conference begins on Monday, and clarity on President Trump's new tariffs on China is anticipated, following threats of a significant increase in tariffs on Chinese imports [2]

Core Viewpoint - The U.S. Food and Drug Administration has approved labeling changes for Johnson & Johnson and Legend Biotech's blood cancer therapy, which now includes a boxed warning for a potentially fatal side effect [1] Group 1 - The FDA's approval indicates a significant regulatory update for the blood cancer therapy developed by Johnson & Johnson and Legend Biotech [1] - The inclusion of a boxed warning highlights the seriousness of the potential side effects associated with the therapy, which may impact its market perception and usage [1]

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC, a limited liability company established pursuant to the laws of the Island of Nevis to purchase up to 500,000 shares of Johnson & Johnson common stock at a price of $145.00 per share in cash. Tutanota's offer price of $145.00 per share was well below the closing price of Johnson & Johnson common stock on September 26, 20. ...

RBC Capital sets a new price target for Johnson & Johnson (NYSE:JNJ) at $209, indicating a potential increase of approximately 9.26%.The potential acquisition of Protagonist Therapeutics could significantly expand JNJ's pharmaceutical portfolio.FDA approval of Simponi for children with ulcerative colitis underscores JNJ's commitment to addressing unmet medical needs.Johnson & Johnson (NYSE: JNJ) is a well-established company known for its diverse range of products in the healthcare sector, including pharmac ...

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. Markets: Stocks were selling off to close the week after President Donald Trump threatened a "massive" tariff increase on China amid a dispute over rare earth minerals. Over the summer, Trump cautioned that he would place steeper tariffs on China if it curbed exports of rare earth magnets. This announcement, however, still surprised the m ...

Group 1: Quarterly Earnings Reports - Major companies like Pepsi, Delta, and Levi have started reporting quarterly results, indicating the health of the global consumer [1] - A significant wave of earnings reports from mega-banks and other key players such as ASML, Taiwan Semiconductor, and Johnson & Johnson is expected next week [1] - The busiest period for Q3 earnings is anticipated in the last week of October, with a heavy reporting schedule from mid-October through mid-November [1] Group 2: Gold Market Insights - Gold futures have recently surpassed $4,000/oz for the first time, generating widespread discussion in financial news [2] - Various financial institutions, including Goldman Sachs, have made bullish forecasts for gold prices, with predictions reaching as high as $4,900/oz by the end of next year [3] - The current volatility in gold prices is seen as a reflection of broader market conditions, with many stocks performing well due to various narratives, including advancements in AI and government spending [4]

Welcome back to Money Movers. Take a look at the XBI biotech ETF on pace for its best year since 2020. And news breaking earlier from the Wall Street Journal that Johnson and Johnson is looking to buy Protagonist Therapeutics.Our ne next guest is a top shareholder in Protagonist and a longtime investor in the biotech space. Joining us now, RTW Investments managing partner and CIO, Dr. . Rod Wong.Dr. . Thank you for being here today. Um, so there's been a a string of acquisitions in this space in in recent w ...

Key Takeaways J&J will report third-quarter 2025 results on Oct. 14, kicking off the earnings season for pharma players.Sales growth is expected from Darzalex, Tremfya, Erleada and new drugs like Carvykti and Tecvayli.Stelara faces steep biosimilar competition, while MedTech faces China-related headwinds.Johnson & Johnson (JNJ) will begin the earnings season for the drug & biotech sector when it reports its third-quarter 2025 results on Oct. 14. The Zacks Consensus Estimate for third-quarter sales and earni ...

Johnson & Johnson (NYSE:JNJ) is reportedly in discussions to acquire Protagonist Therapeutics (NASDAQ:PTGX).Citing people close to the talks, the Wall Street Journal reported that the deal is not guaranteed, and the terms have yet to be finalized.Year to date, Protagonist Therapeutics' stock has gained around 132%, as per data from Benzinga Pro.Partnership May Evolve Into Full OwnershipJohnson & Johnson and Protagonist already share a collaboration to develop an oral therapy targeting plaque psoriasis and u ...

Exclusive: Johnson & Johnson is in talks to buy Protagonist Therapeutics in a deal that would solidify the companies’ existing partnership in creating a treatment for ulcerative colitis https://t.co/BNb7Po7tF7 ...